Patents
Literature
16 results about "Neuroactive steroid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.
Neuroactive steroids, compositions, and uses thereof
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC
3. Alpha-hydroxy, 17-beta-C(O)-N-aryl-substituted neuroactive steroids and compositions thereof
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids, compositions, and uses thereof
InactiveUS20260116911A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC
Neuroactive steroid solid dispersion, solid dispersion composition, method for preparing same and use thereof, and drug comprising solid dispersion
PCT designated stageWO2026077307A1Organic active ingredientsPowder deliveryPlasticizerNeuroactive steroid
The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Owner:BEIJING HORICIN BIOTECHNOLOGY CO LTD
Neuroactive steroids and their methods of use
Owner:SAGE THERAPEUTICS INC
Neuroactive steroid formulations and methods of use thereof
Owner:SAGE THERAPEUTICS INC
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
Owner:SAGE THERAPEUTICS LLC
NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
Owner:SAGE THERAPEUTICS INC
9(11)-unsaturated neuroactive steroids and methods of use thereof
ActiveCN113227114BOrganic active ingredientsAndrostane derivativesNeuroactive steroidPharmaceutical drug
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids and methods of use thereof
Owner:SAGE THERAPEUTICS LLC
Crystal form of neuroactive steroid derivative and use thereof
The present invention belongs to the technical field of medicine. Provided are a crystal form of a neuroactive steroid derivative and the use thereof. For the crystal form of the neuroactive steroid derivative (having a structure represented by formula (I)), the characteristic diffraction peaks in an X-ray powder diffraction pattern expressed as 2θ angles using Cu-Kα radiation include 11.450±0.200°, 15.724±0.200°, 19.040±0.200°, 22.955±0.200° and 24.975±0.200°. The crystal form has good flowability, no electrostatic phenomenon, high stability, and almost no hygroscopicity, and remains stable under high temperature, high humidity and light exposure conditions. The crystal form has a strong positive modulatory effect on a GABAA receptor, and has favorable pharmacokinetic properties and a favorable oral absorption rate. Therefore, the crystal form can be applied in the preparation of oral and other dosage forms of drugs with a high efficacy against diseases such as postpartum depression.
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD
Crystal form of neuroactive steroid derivative and use thereof
Provided are a crystal form of a neuroactive steroid derivative and use thereof, belonging to the field of pharmaceutical technology. The crystal form of the neuroactive steroid derivative (having a structure represented by formula I) provided by the present disclosure has characteristic diffraction peaks expressed as 2θ angles in an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, including 11.450 ± 0.200°, 15.724 ± 0.200°, 19.040 ± 0.200°, 22.955 ± 0.200° and 24.975 ± 0.200°. The crystal form provided by the present disclosure exhibits good flowability, no electrostatic phenomenon, and high stability, and is almost non-hygroscopic, and can remain stable under high temperature, high humidity and light irradiation conditions. The crystal form has a strong positive modulatory effect on GABAA receptors, has good pharmacokinetic properties and oral absorption rate, and thus can be used for preparation of a drug in oral or other dosage forms for efficiently treating diseases such as postpartum depression.
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD
Steroid blockers of t-type calcium channels for treatment of pain
PCT designated stageWO2026064400A1Organic active ingredientsNervous disorderNeuroactive steroidIonic Channels
Among the various aspects of the present disclosure is the provision of neuroactive steroid compositions and methods of use thereof. Disclosed herein are neuroactive steroid compositions that inhibit a voltage-gated calcium ion channel for use in the treatment of pain. Methods to treat pain that includes administering a neuroactive steroid composition to a subject in need is also disclosed.
Owner:WASHINGTON UNIV IN SAINT LOUIS +2
Position 10: Substituted neuroactive steroids with a cyclic group for use in the treatment of central nervous system disorders
ActiveDE602019083579T2Organic active ingredientsNervous disorderNeuroactive steroidMedicinal chemistry
Owner:SAGE THERAPEUTICS INC